Financial statements Notes to the financial statements 29 Other provisions Legal Major Employee and other restructuring related Other disputes programmes provisions provisions Total m m m m m At 1 January 2013 527 373 227 265 1,392 Exchange adjustments 20 1 1 1 21 Charge for the year 286 179 54 138 657 Reversed unused 36 15 2 32 85 Unwinding of discount 1 6 7 14 Utilised 115 189 18 97 419 Reclassifications and other movements 3 4 7 6 At 31 December 2013 646 349 260 289 1,544 To be settled within one year 635 160 34 163 992 To be settled after one year 11 189 226 126 552 At 31 December 2013 646 349 260 289 1,544 It is in the nature of the Groups business that a number of Legal and other disputes these matters may be the subject of negotiation and litigation over The Group is involved in a substantial number of legal and other many years.
Litigation proceedings, including the various appeal disputes, including notification of possible claims, as set out in procedures, often take many years to reach resolution, and out-ofNote 44 Legal proceedings.
Provisions for legal and other disputes court settlement discussions can also often be protracted.
The include amounts relating to product liability principally relating to Group is in potential settlement discussions in a number of the Avandia, Paxil and Poligrip, anti-trust principally relating to disputes for which amounts have been provided and, based on its Wellbutrin, Flonase and Lamictal, government investigations current assessment of the progress of these disputes, estimates principally relating to the Colorado investigation settlement, that 0.6 billion of the amount provided at 31 December 2013 will Avandia-related investigations, Average Wholesale Price AWP be settled within one year.
and nominal price investigations, contract terminations, selfinsurance, environmental clean-up and property rental.
At 31 December 2013, it was expected that 1 million 2012 3 million of the provision made for legal and other disputes will be The charge for the year of 286 million 251 million net of reversals reimbursed by third party insurers.
This amount is included within the and estimated insurance recoveries primarily related to provisions Other receivables balances in Note 22, Other non-current assets for product liability cases regarding Paxil, Poligrip and other and Note 24, Trade and other receivables.
For a discussion of legal products and various government investigations.
issues, see Note 44, Legal proceedings.
The discount on the provisions decreased by nil in 2013 2012 3 million and was calculated using risk-adjusted projected cash flows and risk-free rates of return.
The movement in 2013 includes a decrease of nil 2012 1 million arising from a change in the discount rate in the year.
In respect of product liability claims related to certain products, there is sufficient history of claims made and settlements to enable management to make a reliable estimate of the provision required to cover unasserted claims.
The ultimate liability for such matters may vary from the amounts provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement negotiations.
